Evogene Announces Expanded Collaboration with Google Cloud to Integrate AI Agents into ChemPass AI™
Evogene (NASDAQ: EVGN) announced on February 10, 2026 an expanded collaboration with Google Cloud to integrate advanced AI agents into its ChemPass AI™ platform using Google Cloud Vertex AI.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
Evogene (NASDAQ: EVGN) announced on February 10, 2026 an expanded collaboration with Google Cloud to integrate advanced AI agents into its ChemPass AI™ platform using Google Cloud Vertex AI. The phase aims to accelerate and scale small-molecule discovery, shorten design–make–test–analyze cycles, and enable parallel molecular exploration.
The move follows a prior October 2024 milestone that built a generative AI foundation model now core to ChemPass AI™. Evogene said the partnership could broaden offerings, improve speed and cost structure, and make some tools available via Google Cloud Marketplace.
Details
News Market Reaction – EVGN
On Feb 10, the day this news came out, EVGN closed 7.34% below the previous close.
Data tracked by StockTitan Argus for the Feb 10 session.
Key Figures
- Current price
- $1.09
- Prior close before Google Cloud AI collaboration release
- 52-week range
- $0.93–$2.42
- 52-week low and high for EVGN
- Market cap
- $9,415,648
- Equity value prior to expanded collaboration announcement
- Volume vs. average
- 75,565 vs. 705,543
- Today’s volume vs. 20-day average; relative volume 0.11
- Global castor oil market
- USD 2.4 billion
- Casterra/Fantini release cited 2025 market value
- Castor oil 2030 forecast
- USD 3.09 billion
- Casterra/Fantini release projected 2030 market
- Castor oil CAGR
- 5.20% CAGR
- Projected growth rate to 2030 from Casterra/Fantini release
- Experience in biotech
- 15 years
- Dr. Olga Nissan’s experience noted in Dec 30, 2025 release
Historical Context
-
Added two academic experts to strengthen ChemPass AI scientific leadership.
-
Biomica licensed BMC128 globally to Lishan with milestones and royalties.
-
Teamed with Unravel Biosciences on first-in-class demyelination therapy.
-
Appointed experienced BD leader to scale ChemPass AI collaborations.
-
Casterra–Fantini deal to mechanize scalable commercial castor farming.
24h Move is the share-price change in the day after each event; other market factors may also have contributed.
AI-generated analysis. How Rhea-AI works. Not financial advice.
The new collaboration is expected to accelerate, scale and advance small-molecule discovery and optimization for pharmaceutical and agricultural products
REHOVOT,
This announcement marks the second major milestone in the partnership between Evogene and Google Cloud, following the successful collaboration announced in October 2024. The initial phase focused on building a generative AI foundation model that now serves as a core component of ChemPass AI™. This powerful capability drove Evogene's recent collaborations, and the addition of our new agent technology positions the company to broaden its offering and accelerate future partnerships.
AI agents represent a new generation of artificial intelligence systems that can independently plan, reason, and execute complex, multi-step scientific workflows. When integrated into ChemPass AI™, these agents are designed to automate and scale key discovery processes, enable large-scale parallel molecular exploration, shorten design–make–test–analyze cycles, and improve the accuracy and success rate of designing small-molecule based products.
These capabilities directly support Evogene's core objective: identifying high-quality small molecules that meet multiple, stringent criteria required to become commercially viable product candidates. The expanded collaboration is expected to further strengthen Evogene's position as a leader in next-generation molecular design for both pharmaceutical and agricultural markets.
Boaz Maoz, Managing Director, Google Cloud Israel, commented:
"This expanded collaboration with Evogene demonstrates the power of integrating cutting-edge artificial intelligence into scientific research. By leveraging our technology to deploy advanced AI agents, we are enabling Evogene to automate and scale their complex discovery workflows. This foundation accelerates the speed and precision of identifying small molecules, further cementing Evogene's role as a leader in next-generation molecular design for the pharmaceutical and agricultural industries."
Ofer Haviv, President and CEO of Evogene, said: "Evogene is pleased to further expand its collaboration with Google Cloud. The integration of AI agents into ChemPass AI™ is expected to improve our speed, cost structure, and ability to run multiple discovery programs in parallel. We are also excited about the potential to make parts of our real-world innovation tools globally accessible through Google Cloud Marketplace. This collaboration marks for us a shift from AI models to autonomous discovery, as ChemPass AI™ enters a new phase of scale and execution."
About Evogene Ltd.
Evogene Ltd. (NASDAQ: EVGN) (TASE: EVGN) is a pioneering company in computational chemistry, specializing in the generative design of small molecules for the pharmaceutical and agricultural industries.
At the core of its technology is ChemPass AI™, a proprietary generative AI engine that enables the design of novel, highly potent small molecules optimized across multiple critical parameters. This powerful platform significantly improves success rates while reducing development time and costs.
Built on this powerful technological foundation, and through strategic partnerships alongside internal product development, Evogene is focused on creating breakthrough products driven by the integration of scientific innovation with real-world industry needs. We call this approach "Real-World Innovation".
Learn more at: www.evogene.com.
Forward-Looking Statements
This press release contains "forward-looking statements" relating to future events. These statements may be identified by words such as "may," "could," "expects," "hopes," "intends," "anticipates," "plans," "believes," "scheduled," "estimates," "demonstrates" or words of similar meaning. For example, Evogene and its subsidiaries are using forward-looking statements in this press release when it discusses the success of the collaboration to increase the speed, precision, and efficiency of identifying and optimizing small molecules for drug and ag-chemical development, the success of Evogene to broaden its offering and accelerate future partnerships, the integration of AI agents into ChemPass AI™ which is expected to result in automate and scale key discovery processes, enable large-scale parallel molecular exploration, shorten design–make–test–analyze cycles, and improve the accuracy and success rate of designing small molecules based products and Evogene's position as a leader in next-generation molecular design for both pharmaceutical and agricultural markets. Such statements are based on current expectations, estimates, projections and assumptions, describe opinions about future events, involve certain risks and uncertainties which are difficult to predict and are not guarantees of future performance. Therefore, actual future results, performance or achievements of Evogene and its subsidiaries may differ materially from what is expressed or implied by such forward-looking statements due to a variety of factors, many of which are beyond the control of Evogene and its subsidiaries, including, without limitation, the current war between
Evogene Investor Relations Contact:
Email: ir@evogene.com
Tel: +972-8-9311901
Logo: https://mma.prnewswire.com/media/2814604/Evogene_Logo.jpg
View original content:https://www.prnewswire.com/news-releases/evogene-announces-expanded-collaboration-with-google-cloud-to-integrate-ai-agents-into-chempass-ai-302683508.html
SOURCE Evogene
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.